Does bright light therapy help non-seasonal depression?

Bright light therapy — a fixture of treatment for seasonal depression — has a smaller but genuine evidence base in non-seasonal major depressive disorder, where the best single randomised trial found morning light, on its own and combined with an antidepressant, beat a sham device over eight weeks [s1]. The important qualifier is that the benefit is most consistent when light is added to a drug rather than used alone, and the trials are small and short [s1][s2].

What the trial tested

The anchor study is an eight-week randomised, double-blind, placebo- and sham-controlled trial in adults aged 19 to 60 with non-seasonal MDD of at least moderate severity, treated in academic outpatient psychiatry clinics [s1]. It randomised 122 patients to one of four arms: light monotherapy (a 10,000-lux fluorescent white light box for 30 minutes each morning plus a placebo pill); antidepressant monotherapy (an inactive negative-ion generator plus fluoxetine hydrochloride 20 mg/d); the combination of light and fluoxetine; or placebo (inactive ion generator plus placebo pill) [s1].

The primary outcome was the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to week eight [s1]. Mean MADRS improvement was 13.4 points in the light group, 8.8 in the fluoxetine group, 16.9 in the combination group, and 6.5 in the placebo group [s1].

What it found

Two arms clearly separated from placebo. The combination reached an effect size of d = 1.11 (95% CI 0.54 to 1.64) and light monotherapy d = 0.80 (95% CI 0.28 to 1.31), both statistically superior to placebo [s1]. Fluoxetine alone did not separate from placebo in this trial: d = 0.24 (95% CI −0.27 to 0.74) [s1].

The response rates — a fall of at least 50% in MADRS score — tell the same story. Response was achieved by 33.3% on placebo, 29.0% on fluoxetine, 50.0% on light, and 75.9% on the combination [s1]. Remission (a MADRS score of 10 or below) followed the same order: 30.0%, 19.4%, 43.8% and 58.6% respectively [s1].

Reading it honestly

The headline finding — that light plus an antidepressant roughly doubled the placebo response rate — is striking, but it rests on 122 people followed for eight weeks in a handful of academic clinics [s1]. A single trial of that size establishes a signal, not a settled dose or duration.

There is also a genuine tension in the wider literature. This trial found light monotherapy superior to placebo [s1], but a 2025 systematic review of phototherapy for non-seasonal depression concluded that light alone has limited effectiveness and that its clearest benefit appears when it is combined with antidepressants, using multiple daily sessions tailored to the patient, sometimes at lower intensities [s2]. The review reported that phototherapy was well tolerated, with only minor and transient side effects and no serious ones [s2].

Blinding is the hard problem underneath all of this. A bright light box is difficult to conceal; patients can often tell whether their device is the active one, and a sham that is obviously dim may inflate the apparent drug-versus-light contrast. The trial used an inactive negative-ion generator as its sham precisely to address this, but no design fully removes the issue [s1].

What it means for a reader

The evidence supports bright light as a low-risk option in non-seasonal depression that is best understood as an adjunct — something added to standard treatment — rather than a replacement for it [s1][s2]. The protocol with the most evidence behind it is morning exposure to a 10,000-lux box for about 30 minutes; the trial delivered it in the early morning [s1]. This is informational, not a treatment recommendation, and light therapy can interact with bipolar disorder and some eye conditions, which is why the timing and suitability are clinical decisions.

What to watch

Whether larger, longer trials replicate the combination effect and pin down who benefits, and whether the field converges on a standard for session number, timing and intensity — the very parameters the 2025 review flagged as the difference between a device that works and one that does not [s2]. Until then, the honest summary is a real but modestly evidenced adjunct, strongest alongside a drug and weakest as a stand-alone cure.

This article is informational and is not medical advice.

Sources

• Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder — JAMA Psychiatry, 2015-11-18
• The Use of Phototherapy for the Treatment of Non-Seasonal Depression: A Systematic Review — Journal of Clinical Medicine, 2025-03-05